Prostamax — Research, Dosing & Price Guide

Prostamax is a bioregulator peptide complex developed by the Khavinson laboratory that targets prostate tissue. It is designed to normalize prostate gland function, reduce inflammation, and support healthy cell differentiation in aging prostate tissue. As a bioregulator, it works through epigenetic modulation of gene expression in prostatic cells.

Prostamax contains short peptides that penetrate prostate cell membranes and interact with DNA sequences to modulate gene expression related to prostate-specific antigen (PSA) regulation, anti-inflammatory pathways, and normal cell proliferation/differentiation balance. It normalizes the production of prostatic enzymes and growth factors while reducing the expression of inflammatory cytokines (IL-6, TNF-α) that contribute to benign prostatic hyperplasia (BPH) and chronic prostatitis. The peptides also modulate the local hormonal microenvironment by influencing 5-alpha-reductase and androgen receptor expression in prostatic tissue.

• Khavinson et al. demonstrated Prostamax normalized prostate tissue function in aged animal models
• Studies showed bioregulator peptides reduced inflammatory markers in prostate tissue cultures
• Russian clinical observations reported improved urinary symptoms and reduced PSA levels in elderly men after Prostamax cycles
• Preclinical research showed normalization of prostate cell proliferation patterns, suggesting anti-hyperplastic effects

• Oral: 10–20 mg daily in capsule form for 10–30 days
• Repeat cycles every 3–6 months
• For active prostate support: 20 mg daily for 20–30 days
• For maintenance: 10 mg daily for 10–15 days every 4–6 months
• Can be combined with other prostate-supportive interventions

Known Side Effects

• No significant adverse effects reported in published research
• Mild GI discomfort — infrequently reported with oral dosing
• Very limited clinical safety data
• Theoretical interaction with hormonal prostate therapies

Safety Profile

Prostamax has a favorable safety profile consistent with the Khavinson bioregulator family. No serious adverse events have been reported in published studies. However, human clinical trial data is very limited, and most evidence is from preclinical and observational Russian studies. Men with diagnosed prostate cancer should consult their oncologist before using any prostate-targeted compound. Prostamax should not be used as a substitute for established medical treatment for BPH or prostate cancer.

Days 1–10: No immediate subjective effects expected. Epigenetic modulation of prostate gene expression begins at the cellular level. Days 10–30: Some users report improved urinary symptoms (reduced frequency, improved flow) if BPH-related symptoms were present. PSA levels may begin to normalize. Post-cycle: Benefits persist for weeks to months. Repeated cycles every 3–6 months provide cumulative improvement in prostate tissue function.

Prices sourced from peptides.gg marketplace. Prices may vary.